Susmed's Total Assets for the quarter that ended in Dec. 2025 was 円4,271.1 Mil.
During the past 12 months, Susmed's average Total Assets Growth Rate was 107.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 38.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 39.20% per year.
During the past 6 years, Susmed's highest 3-Year average Total Assets Growth Rate was 50.20%. The lowest was 20.90%. And the median was 38.30%.
Total Assets is connected with ROA %. Susmed's annualizedROA % for the quarter that ended in Dec. 2025 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Susmed's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Susmed's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Susmed Total Assets Related Terms
Susmed Total Assets Historical Data
* Premium members only.
The historical data trend for Susmed's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Susmed's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a Total Assets of 円4,271.1 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Susmed and its competitors.
Is Susmed's Total Assets too high?
Susmed's current Total Assets is 円4,271.1 Mil. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Total Assets compare to VEEV and BTSG?
Susmed's Total Assets of 円4,271.1 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Healthcare Providers & Services company?
A good Total Assets depends on the Healthcare Providers & Services industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Susmed and its competitors. Susmed's current Total Assets is 円4,271.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円844.57, compared to a current price of 円696.00 — trading 17.6% below its estimated fair value. The current Total Assets is 円4,271.1 Mil. Susmed's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Susmed (TSE:4263), the current Total Assets is 円4,271.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円696.00 is trading 17.6% below its estimated GF Value™ of 円844.57.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
Total Assets: 円4,271.1 Mil
GF Value™: 円844.57 vs. price of 円696.00 (17.6% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score
Get the complete analysis for TSE:4263
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
